Abstract: The invention refers to a device for inhibiting the neural activity of a carotid sinus nerve (CSN) or carotid body of a subject, the device comprising: one or more transducers configured to apply a signal to the CSN or associated carotid body of the subject, optionally at least two such transducers; and a controller coupled to the one or more transducers, the controller controlling the signal to be applied by the one or more transducers, such that the signal inhibits the neural activity of the CSN or carotid body to produce a physiological response in the subject, wherein the physiological response is one or more of the group consisting of: an increase in insulin sensitivity in the subject, an increase in glucose tolerance in the subject, a decrease in (fasting) plasma glucose concentration in the subject, a reduction in subcutaneous fat content in the subject, and a reduction in obesity in the subject.

Abstract: The invention refers to a device for inhibiting the neural activity of a carotid sinus nerve (CSN) or carotid body of a subject, the device comprising: one or more transducers configured to apply a signal to the CSN or associated carotid body of the subject, optionally at least two such transducers; and a controller coupled to the one or more transducers, the controller controlling the signal to be applied by the one or more transducers, such that the signal inhibits the neural activity of the CSN or carotid body to produce a physiological response in the subject, wherein the physiological response is one or more of the group consisting of: an increase in insulin sensitivity in the subject, an increase in glucose tolerance in the subject, a decrease in (fasting) plasma glucose concentration in the subject, a reduction in subcutaneous fat content in the subject, and a reduction in obesity in the subject.

Abstract: Modulation of neural activity in the superior laryngeal nerve (SLN) or cervical sympathetic trunk (CST) is effective in treating diseases and conditions mediated by thyroid and parathyroid hormones, in particular diseases associated with calcitonin secretion (e.g. osteoporosis) or diseases associated with thyroxine secretion (e.g. hypothyroid syndrome).

Abstract: The invention provides devices, apparatuses, systems and methods for treating and ameliorating inflammation of the gut. In particular, the invention provides devices, apparatuses and methods in which a neuromodulatory signal is delivered a splenic nerve and/or superior mesenteric plexus (SMP). The signal is able to treat inflammatory disorders, e.g., colitis, for example in Inflammatory Bowel Disease.

Abstract: The invention provides devices, apparatuses, systems and methods for treating and ameliorating inflammation of the gut. In particular, the invention provides devices, apparatuses and methods in which a neuromodulatory signal is delivered a splenic nerve and/or superior mesenteric plexus (SMP). The signal is able to treat inflammatory disorders, e.g., colitis, for example in Inflammatory Bowel Disease.

Abstract: The present invention relates to the use of a composition as a fungicide, wherein said composition comprises at least one compound of formula (I) or formula (II) wherein wherein R2, R3, R4, R5, R6 and R7 are independently of each other H, OH or OCH3.

Abstract: Methods for treating polycystic ovarian syndrome with a neuromodulation device that modulates sympathetic neural activity are described herein. The neuromodulation device is an apparatus for the treatment of polycystic ovarian syndrome. In one aspect, the apparatus decreases the neural activity of a postganglionic ovary-innervating sympathetic nerve. Modulation in neural activity may be achieved using an apparatus comprising one or more stimulators each configured to apply a signal to a postganglionic ovary-innervating sympathetic nerve of the patient, a controller coupled to the one or more stimulators, the controller controlling the signal to be applied by each of the one or more stimulators, such that the signal decreases the neural activity of the nerve to produce a physiological and/or biochemical response in the patient, wherein the physiological and/or biochemical response comprises an improvement in one or more symptoms of polycystic ovarian syndrome.

Abstract: Modulation of neural activity in the superior laryngeal nerve (SLN) or cervical sympathetic trunk (CST) is effective in treating diseases and conditions mediated by thyroid and parathyroid hormones, in particular diseases associated with calcitonin secretion (e.g. osteoporosis) or diseases associated with thyroxine secretion (e.g. hypothyroid syndrome).

Abstract: The present invention relates to the use of a composition as a fungicide, wherein said composition comprises at least one compound of formula (I) or formula (II), wherein R1=formula (IV) or Formula (V), wherein R2, R3, R4; R5, R6 and R7 are independently of each other H, OH or OCH3.

Abstract: The present invention provides improved devices, systems and methods to provide for control of bladder function. Aspects of the present disclosure relate to an apparatus, system and/or a method for modulating the neural activity of afferent fibres of the pelvic nerve to bladder function. In one aspect, the disclosure relates to the use of pharmaceutical compositions in patients undergoing neuromodulation therapy.

Abstract: The invention provides devices, apparatuses, systems and methods for treating and ameliorating inflammation of the gut. In particular, the invention provides devices, apparatuses and methods in which a neuromodulatory signal is delivered a splenic nerve and/or superior mesenteric plexus (SMP). The signal is able to treat inflammatory disorders, e.g., colitis, for example in Inflammatory Bowel Disease.

Abstract: The present invention relates to medical devices and, more particularly, to medical devices that deliver neuromodulating therapy.

Abstract: The invention refers to a device for inhibiting the neural activity of a carotid sinus nerve (CSN) or carotid body of a subject, the device comprising: one or more transducers configured to apply a signal to the CSN or associated carotid body of the subject, optionally at least two such transducers; and a controller coupled to the one or more transducers, the controller controlling the signal to be applied by the one or more transducers, such that the signal inhibits the neural activity of the CSN or carotid body to produce a physiological response in the subject, wherein the physiological response is one or more of the group consisting of: an increase in insulin sensitivity in the subject, an increase in glucose tolerance in the subject, a decrease in (fasting) plasma glucose concentration in the subject, a reduction in subcutaneous fat content in the subject, and a reduction in obesity in the subject.

Abstract: This invention relates to a data system that anonymizes personalized event data, by receiving the personalized event data containing an encrypted personal identifier and determining whether an entry exists for the encrypted personal identifier in a key database. The encrypted personal identifier may be associated with a system identifier that uniquely identifies the encrypted personal identifier and is uniquely associated to one system identifier. If no entry is detected in the key database for the received encrypted personal identifier, then a new entry for the key database is generated in which the received encrypted personal identifier is uniquely associated to a new system identifier.

Abstract: This invention relates to a data system that anonymizes personalized event data, by receiving the personalized event data containing an encrypted personal identifier and determining whether an entry exists for the encrypted personal identifier in a key database. The encrypted personal identifier may be associated with a system identifier that uniquely identifies the encrypted personal identifier and is uniquely associated to one system identifier. If no entry is detected in the key database for the received encrypted personal identifier, then a new entry for the key database is generated in which the received encrypted personal identifier is uniquely associated to a new system identifier.

Abstract: The disclosure relates to a photovoltaic element having a sealing web with at least one photovoltaic module which is mounted on one side of the sealing web and has contact points and electrical connections. The contact points of the photovoltaic module can be arranged on a side facing the sealing web, and the electrical connections can pass through the sealing web.

Abstract: The invention is directed to two coupled vehicles (1) such as railbound vehicles or articulated busses, with a connection with at least one bellows (2) as well as with a coupling device comprising two coupling frames (4, 5), said coupling frames (4, 5) comprising interengaging male and female coupling members (10, 15), a locking member (30) being provided for respectively locking the male coupling members (15) in the female coupling members (10), said locking member (30) being slidably guided by the respective locking member (4, 5), said locking member (30) communicating with a force transmitting member (9) that is slidably guided in the respective one of the coupling frames (4, 5), the force transmitting member (9) transmitting both tensile and shear forces.

Abstract: The invention relates to the detection of the binding of analyte molecules, for example biopolymer molecules, to immobilized capture substance molecules. The invention consists in using semiconductor wafers (chips) with electrical circuits in spatial proximity to a surface area coated with capture substance molecules and loading the binding of the analyte molecules to the capture substance molecules with co-bound electrically conductive nanoparticles so that the nanoparticles can act upon the electrical circuits either through changes in the electrical stray capacitance or by generating electric currents, thus making the binding of the analyte molecules electronically detectable.

Abstract: The invention is directed to two coupled vehicles (1) such as railbound vehicles or articulated busses, with a connection with at least one bellows (2) as well as with a coupling device comprising two coupling frames (4, 5), said coupling frames (4, 5) comprising interengaging male and female coupling members (10, 15), a locking member (30) being provided for respectively locking the male coupling members (15) in the female coupling members (10), said locking member (30) being slidably guided by the respective locking member (4, 5), said locking member (30) communicating with a force transmitting member (9) that is slidably guided in the respective one of the coupling frames (4, 5), the force transmitting member (9) transmitting both tensile and shear forces.

Abstract: The invention is related to a method for treating or preventing a disorder resulting from the release of bradykinin in said mammal, particularly a mammal which produces a HBP which binds to a HBP antagonist, e.g. a monoclonal antibody that binds to at least one epitope of human HBP, comprising administering to said mammal a HBP antagonist in an amount effective to decrease the release of bradykinin in a mammal. Furthermore, the invention is directed to methods and kits for determining if a mammal produces HBP that binds to a HBP antagonist, e.g., a monoclonal antibody that binds to at least one epitope of human HBP and a method for detecting an antagonist of HBP.